Advenio is a deep tech company solving healthcare diagnostics using AI, machine learning, data science, and advanced image processing. Their innovative software solution works on differential diagnosis to detect crucial and complex diseases from medical images and mitigate uncertainties in interpretation, making it faster, cheaper, and more robust than traditional methods. The Advenio platform is positioned to serve across the panel: from eye and diabetic clinics to insurance and pharmaceuticals. Their AI system significantly restructures the current workflow of hospitals and public health screenings, thereby reducing a doctor's administrative burden. While their initial go-to-market solution is retinal image processing, Advenio is actively researching and developing solutions for ophthalmology, endocrinology, the cardiovascular system, neurology and also Alzheimer's and Parkinson's. Due to the nature of how systemic diseases manifest in the retina, Advenio's software is effectively capable of detecting hundreds of diseases and complications from the back of the eye with high accuracy. With this software, hospitals can see a 4-15 percent increase in revenue, while billions of patients across the globe can benefit from more affordable access to quality healthcare.
Democratizing healthcare with an AI-powered software that rapidly, affordably, and reliably diagnoses critical health conditions from medical images.
FOUNDED
2010
AREAS OF IMPACT
Health Infrastructure
HEADQUARTERS
Chandigarh, Chandigarh, India
COMPANY SIZE
6–20
Mausumi Acharyya (Founder, CEO at Advenio) has been an Unreasonable Fellow since June 2018 and most recently participated in Unreasonable Impact Asia Pacific 2018.
Connect with Advenio
Follow Advenio on social media below or check for open jobs on their careers page.